J. Morales-Ramirez

发表

Efficacy of a tetravalent dengue vaccine in children in Latin America.

G. Carrasquilla, R. Dietze, M. Saville, 2015, The New England journal of medicine.

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

K. Tashima, D. Skiest, J. Stanford, 1999, The New England journal of medicine.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

P. Sax, C. Stedman, D. Dieterich, 2015, The New England journal of medicine.

Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial

J. Gatell, H. Teppler, F. Raffi, 2019, Antiviral therapy.

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

J. Gatell, H. Teppler, Charlotte M. Harvey, 2014, Journal of the International AIDS Society.

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

C. Crumpacker, C. Kovacs, R. Danovich, 2009, Journal of acquired immune deficiency syndromes.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

D. Ward, J. Gallant, M. Johnson, 2016, The lancet. HIV.

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

K. Ruxrungtham, E. Katabira, D. Steyn, 2010, AIDS.

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults

K. Russell, R. Rupp, B. Coller, 2022, Human vaccines & immunotherapeutics.

Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004)

H. Teppler, E. Gotuzzo, B. Nguyen, 2012, Journal of acquired immune deficiency syndromes.

Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

C. Kovacs, D. Cooper, R. Steigbigel, 2006, Journal of acquired immune deficiency syndromes.

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study

C. Crumpacker, C. Kovacs, H. Teppler, 2007, Journal of acquired immune deficiency syndromes.

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.

K. Ruxrungtham, A. Pozniak, B. Grinsztejn, 2011, AIDS research and human retroviruses.

Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1-Infected Virologically Suppressed Adults

A. Lazzarin, A. Rachlis, A. Cheng, 2015 .

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients

D. Ward, R. Ebrahimi, J. Morales-Ramirez, 2009, Journal of acquired immune deficiency syndromes.

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

Samit R. Joshi, J. Bogner, J. Molina, 2018, PloS one.

Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naïve, HIV-1-infected ARTEMIS patients …

J. Morales-Ramirez, L. Lavreys, E. Baraldi, 2009 .